Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
17 Maggio 2022 - 2:00PM
Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”)
(Nasdaq: FNCH), a clinical-stage microbiome therapeutics company
leveraging its Human-First Discovery® platform to develop a novel
class of orally administered biological drugs, today announced that
Mark Smith, PhD, Chief Executive Officer, will present a company
overview at the H.C. Wainwright Global Investment Conference being
held May 23-26, 2022. The presentation will be available on-demand
beginning on Tuesday, May 24, 2022 at 7:00 am ET.
A webcast of the presentation will be available under the
‘Investors & News’ section of the Finch website and will be
archived for approximately 30 days.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics
company leveraging its Human-First Discovery® platform to
develop a novel class of orally administered biological drugs. With
the capabilities to develop both complete and targeted microbiome
therapeutics, Finch is advancing a rich pipeline of candidates
designed to address a wide range of unmet medical needs. Finch’s
lead candidate, CP101, is in late-stage clinical development for
the prevention of recurrent C. difficile infection and
has received Breakthrough Therapy and Fast Track designations from
the U.S. Food and Drug Administration. Finch is also developing
FIN-211 for children with autism spectrum disorder and significant
gastrointestinal symptoms. Finch has a partnership with Takeda
focused on the development of targeted microbiome therapeutics for
inflammatory bowel disease. Finch routinely posts information
that may be important to its investors on its website at
https://www.finchtherapeutics.com/. Finch encourages investors to
consult the “Investors & News” section of its website
regularly.
Human-First Discovery® is a registered trademark of Finch
Therapeutics Group, Inc.
Investor Contact:
Stephen JasperGilmartin Group(858)
525-2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public Relations(212)
253-8881jurban@berrypr.com
Grafico Azioni Finch Therapeutics (NASDAQ:FNCH)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Finch Therapeutics (NASDAQ:FNCH)
Storico
Da Giu 2023 a Giu 2024